DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
PR99384
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire=KYODO JBN/ --
DiscGenics, Inc. (
), a privately held, clinical stage biopharmaceutical company focused on
developing regenerative cell-based therapies that alleviate pain and restore
function in patients with degenerative diseases of the spine, today announced
that it will be participating in the 41st Annual J.P. Morgan Healthcare
Conference taking place in San Francisco, CA on January 9 – 12, 2023.
Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg
DiscGenics's Chief Executive Officer and Chairman, Flagg Flanagan will present
on Wednesday, January 11, 2023, at 3:30 p.m. Pacific Time at the Westin St.
Francis in the Golden Gate Room on the 32nd Floor. Flanagan will present a
corporate overview and update of the Company's recently completed clinical
study of its allogeneic progenitor cell therapy (IDCT) for lumbar disc
degeneration.
About DiscGenics
DiscGenics is a privately held, clinical-stage biopharmaceutical company
developing regenerative cell-based therapies that alleviate pain and restore
function in patients with degenerative diseases of the spine. DiscGenics's
first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable
discogenic progenitor cell therapy for symptomatic, mild to moderate lumbar
disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a
manufactured progenitor cell population derived from donated adult human
intervertebral disc tissue, and a viscous carrier. As the only company in the
world to develop an allogeneic cell therapy derived from intervertebral disc
cells to treat diseases of the disc, DiscGenics has a unique opportunity to
offer a non-surgical, potentially regenerative solution for the treatment of
patients suffering from the debilitating effects of back pain. For more
information, visit www.discgenics.com .
SOURCE: DiscGenics, Inc.
CONTACT: Lindsey Saxon, lindsey@discgenics.com; Colin Novick (Japan),
colin.lee.novick@cj-partners.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
